Taking people in DenmarkPhase 1
Tests antibodies against chronic hepatitis B in adults in a dose study
Tests antibodies against chronic hepatitis B in adults over 18.
Plain-language title generated from the registry record
Registry title: An ascending dose study to determine the safety and effect of antibodies against hepatitis B (The SAMBA Study)
Key facts
- Where
- Aalborg, Aarhus N, Hvidovre, København Ø, Kolding, and Odense C, DenmarkSee the 6 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic hepatitis B infection. It tests the safety and effect of antibodies against hepatitis B at rising doses.
- Age
- 18 years or older
- Sex
- All sexes can join
Main reasons for not taking part
- Healthy volunteers cannot join
Read by machine on 9 November 2026.
Where in Denmark
- Aalborg University HospitalAalborg, DenmarkTaking people
- Region MidtjyllandAarhus N, DenmarkTaking people
- Hvidovre HospitalHvidovre, DenmarkTaking people
- RigshospitaletKøbenhavn Ø, DenmarkTaking people
- Kolding SygehusKolding, DenmarkTaking people
- Odense University HospitalOdense C, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorTrial details
- Who runs it
- Region Midtjylland
- Trial code
- EU 2023-508444-22-01
- Record updated
- 30 July 2026